GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (FRA:52U) » Definitions » Market Cap

Hyloris Pharmaceuticals (FRA:52U) Market Cap : €327.60 Mil (As of May. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Hyloris Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was €12.5. Hyloris Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 28.00 Mil. Therefore, Hyloris Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was €350.01 Mil.

Hyloris Pharmaceuticals's quarterly market cap declined from Dec. 2022 (€320.88 Mil) to Jun. 2023 (€305.20 Mil) but then increased from Jun. 2023 (€305.20 Mil) to Dec. 2023 (€350.01 Mil).

Hyloris Pharmaceuticals's annual market cap declined from Dec. 2021 (€473.21 Mil) to Dec. 2022 (€320.88 Mil) but then increased from Dec. 2022 (€320.88 Mil) to Dec. 2023 (€350.01 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hyloris Pharmaceuticals's Enterprise Value for Today is €298.66 Mil.


Hyloris Pharmaceuticals Market Cap Historical Data

The historical data trend for Hyloris Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Market Cap Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 243.34 473.21 320.88 350.01

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 473.21 405.45 320.88 305.20 350.01

Competitive Comparison of Hyloris Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Market Cap falls into.



Hyloris Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Hyloris Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€12.5*28.0004
=

Hyloris Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=€12.5*28.0004
=€350.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals  (FRA:52U) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Hyloris Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (FRA:52U) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (FRA:52U) Headlines

No Headlines